Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-CANOPY
2024-515860-29-00Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of eplerenone in kidney transplant and cardiac remodeling (2 arms), sponsored by CHRU Nancy. Primary endpoint: Primary hierarchical composite endpoint at 36 weeks. Planned start Mar 2025; status: authorised.
02
Drugs
eplerenone
03
Conditions
kidney transplantcardiac remodeling
Beyond the preview
Go deeper on 2024-515860-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515860-29-00.